Key result
No clinical study data is present in the provided text, which consists only of the journal's editorial board information.
In a single-center registry, off-label use of fondaparinux was common, primarily driven by prophylaxis in patients with documented heparin-induced thrombocytopenia.
Off-label fondaparinux use remains common for HIT prophylaxis; leaves open questions on real-world safety and efficacy.
Fondaparinux is an antithrombotic agent with unique properties that may offer benefit to patients beyond the current approved indications. To explore the off-label use versus approved use of fondaparinux, we initiated a single-center registry of fondaparinux use. During the 25-month study period, 219 patients were prescribed fondaparinux: 157 (71.7%) for prophylaxis and 62 (28.3%) patients for the treatment of thrombosis. When fondaparinux was used for prophylaxis in our registry, 94% of patients had documentation of heparin-induced thrombocytopenia (HIT). Fondaparinux warrants further evaluation in patients with HIT or suspected HIT. In the meantime, its off-label use may exceed its use for FDA-approved indications.
No takes yet. Share an insight, caveat, or question.
Labreche et al. (2009) studied this question. No clinical study data is present in the provided text, which consists only of the journal's editorial board information.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: